CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...